000124287 001__ 124287
000124287 005__ 20240228145504.0
000124287 0247_ $$2doi$$a10.1038/bcj.2017.45
000124287 0247_ $$2pmid$$apmid:28548643
000124287 0247_ $$2altmetric$$aaltmetric:20582729
000124287 037__ $$aDKFZ-2017-01183
000124287 041__ $$aeng
000124287 082__ $$a610
000124287 1001_ $$aJaramillo, S.$$b0
000124287 245__ $$aCondensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia.
000124287 260__ $$aLondon [u.a.]$$bNature Publishing Group$$c2017
000124287 3367_ $$2DRIVER$$aarticle
000124287 3367_ $$2DataCite$$aOutput Types/Journal article
000124287 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1510734762_15361
000124287 3367_ $$2BibTeX$$aARTICLE
000124287 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000124287 3367_ $$00$$2EndNote$$aJournal Article
000124287 520__ $$aThe aim of this cohort study was to compare a condensed schedule of consolidation therapy with high-dose cytarabine on days 1, 2 and 3 (HDAC-123) with the HDAC schedule given on days 1, 3 and 5 (HDAC-135) as well as to evaluate the prophylactic use of pegfilgrastim after chemotherapy in younger patients with acute myeloid leukemia in first complete remission. One hundred and seventy-six patients were treated with HDAC-135 and 392 patients with HDAC-123 with prophylactic pegfilgrastim at days 10 and 8, respectively, in the AMLSG 07-04 and the German AML Intergroup protocol. Time from start to chemotherapy until hematologic recovery with white blood cells >1.0 G/l and neutrophils >0.5 G/l was in median 4 days shorter in patients receiving HDAC-123 compared with HDAC-135 (P<0.0001, each), and further reduced by 2 days (P<0.0001) by pegfilgrastim. Rates of infections were reduced by HDAC-123 (P<0.0001) and pegfilgrastim (P=0.002). Days in hospital and platelet transfusions were significantly reduced by HDAC-123 compared with HDAC-135. Survival was neither affected by HDAC-123 versus HDAC-135 nor by pegfilgrastim. In conclusion, consolidation therapy with HDAC-123 leads to faster hematologic recovery and less infections, platelet transfusions as well as days in hospital without affecting survival.
000124287 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000124287 588__ $$aDataset connected to CrossRef, PubMed,
000124287 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, A.$$b1$$udkfz
000124287 7001_ $$aKrauter, J.$$b2
000124287 7001_ $$aMartin, H.$$b3
000124287 7001_ $$aKindler, T.$$b4
000124287 7001_ $$aBentz, M.$$b5
000124287 7001_ $$aSalih, H. R.$$b6
000124287 7001_ $$aHeld, G.$$b7
000124287 7001_ $$aKöhne, C-H$$b8
000124287 7001_ $$aGötze, K.$$b9
000124287 7001_ $$aLübbert, M.$$b10
000124287 7001_ $$aKündgen, A.$$b11
000124287 7001_ $$aBrossart, P.$$b12
000124287 7001_ $$aWattad, M.$$b13
000124287 7001_ $$aSalwender, H.$$b14
000124287 7001_ $$aHertenstein, B.$$b15
000124287 7001_ $$aNachbaur, D.$$b16
000124287 7001_ $$aWulf, G.$$b17
000124287 7001_ $$aHorst, H-A$$b18
000124287 7001_ $$aKirchen, H.$$b19
000124287 7001_ $$aFiedler, W.$$b20
000124287 7001_ $$aRaghavachar, A.$$b21
000124287 7001_ $$aRuss, G.$$b22
000124287 7001_ $$aKremers, S.$$b23
000124287 7001_ $$aKoller, E.$$b24
000124287 7001_ $$aRunde, V.$$b25
000124287 7001_ $$aHeil, G.$$b26
000124287 7001_ $$aWeber, D.$$b27
000124287 7001_ $$aGöhring, G.$$b28
000124287 7001_ $$aDöhner, K.$$b29
000124287 7001_ $$aGanser, A.$$b30
000124287 7001_ $$aDöhner, H.$$b31
000124287 7001_ $$0P:(DE-He78)d8a0e60e5e095f3161ee0de3712409bc$$aSchlenk, Richard$$b32$$eLast author$$udkfz
000124287 773__ $$0PERI:(DE-600)2600560-8$$a10.1038/bcj.2017.45$$gVol. 7, no. 5, p. e564 -$$n5$$pe564 -$$tBlood cancer journal$$v7$$x2044-5385$$y2017
000124287 909CO $$ooai:inrepo02.dkfz.de:124287$$pVDB
000124287 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000124287 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d8a0e60e5e095f3161ee0de3712409bc$$aDeutsches Krebsforschungszentrum$$b32$$kDKFZ
000124287 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000124287 9141_ $$y2017
000124287 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBLOOD CANCER J : 2015
000124287 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000124287 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000124287 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000124287 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000124287 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000124287 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000124287 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000124287 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000124287 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000124287 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000124287 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000124287 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000124287 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000124287 9201_ $$0I:(DE-He78)G040-20160331$$kG040$$lKlinische Studienzentrale$$x1
000124287 980__ $$ajournal
000124287 980__ $$aVDB
000124287 980__ $$aI:(DE-He78)C060-20160331
000124287 980__ $$aI:(DE-He78)G040-20160331
000124287 980__ $$aUNRESTRICTED